- Home
- EIC vs RCKT Comparison
EIC vs RCKT Comparison
Compare EIC & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EIC | RCKT |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.8M | 340.9M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | EIC | RCKT |
|---|---|---|
| Price | $11.19 | $3.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 14 |
| Target Price | $14.00 | ★ $29.12 |
| AVG Volume (30 Days) | 266.9K | ★ 2.1M |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | ★ 11.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $59,262,402.00 | N/A |
| Revenue This Year | $37.84 | N/A |
| Revenue Next Year | $23.33 | N/A |
| P/E Ratio | $9.75 | ★ N/A |
| Revenue Growth | ★ 44.30 | N/A |
| 52 Week Low | $10.81 | $2.19 |
| 52 Week High | $16.39 | $12.65 |
Technical Indicators
Market Signals| Indicator | EIC | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 59.71 |
| Support Level | $10.93 | $3.36 |
| Resistance Level | $11.60 | $4.05 |
| Average True Range (ATR) | 0.23 | 0.20 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 40.26 | 66.86 |
Price Performance
Historical ComparisonAbout EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.